Abstract:The increase in the incidence of antibiotic-resistant bacteria poses a global public health threat. According to a 2019 WHO report, approximately 1.27 million deaths were attributed to antibiotic-resistant bacteria, with many cases linked to specific bacterial species, such as drug-resistant Pseudomonas aeruginosa and Staphylococcus aureus. By 2050, the number of deaths caused by these bacteria is predicted to surpass that caused by cancer. In response to this serious situation, phage therapy, an alternative to antibiotic treatment, has gained attention. Phage therapy involves the use of viruses that target specific bacteria to treat infections. This method has proven effective in multiple clinical cases, particularly for patients with severe infections caused by multidrug-resistant bacteria. For example, there are reports of patients with systemic infections caused by multidrug-resistant Acinetobacter who recovered following phage administration and patients infected with panresistant Pseudomonas aeruginosa who were cured by phage therapy. A key feature of phage therapy is its high specificity. Phages infect only specific bacteria and eliminate them. However, this specificity can also be a disadvantage, as careful selection of the appropriate phage for the target bacteria is needed. Additionally, bacteria can develop resistance to phages, potentially reducing treatment effectiveness over time. Efforts are underway to select, combine, and improve phages to address these challenges. In Belgium, a national phage bank has been established, and in the United States, the University of California, San Diego, has founded Innovative Phage Applications and Therapeutics (IPATH), marking significant progress toward the clinical application of phage therapy in the country. As a result, phage therapy is emerging as a component of personalized medicine, offering a new treatment option against antibiotic-resistant bacteria. The clinical application of phage therapy is particularly important in life-saving treatments for patients with severe bacterial infections, and its use in conjunction with antibiotics could enhance therapeutic outcomes. Continued research and development of this therapy could provide hope for many more patients in the future.

Advances in phage control of three drug-resistant strains

Phage and antibiotic combination therapy:feasibility and challenges

Bacteriophage therapy for drug-resistant Staphylococcus aureus infections

Phage therapy: A targeted approach to overcoming antibiotic resistance

Recent Advances in Phage-Based Therapeutics for Multi-Drug Resistant Acinetobacter baumannii

Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens

Recent Progress in Phage Therapy to Modulate Multidrug-Resistant Acinetobacter baumannii, including in Human and Poultry

Current status of bacteriophage therapy for severe bacterial infections

Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens

From forgotten cure to modern medicine: The resurgence of bacteriophage therapy

Phage therapy combats pandrug-resistant Acinetobacter baumannii infection safely and efficiently

Biocontrol of methicillin-resistant Staphylococcus aureus using a virulent bacteriophage derived from a temperate one

Bacteriophages show promise as antimicrobial agents

Acinetobacter Baumannii Phages: Past, Present and Future

Phage therapy: A novel approach against multidrug-resistant pathogens

Diversified repertoire of phage resistance in and bidirectional steering effects impacting antibiotic susceptibility

Antimicrobial resistance: use of phage therapy in the management of resistant infections

Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier

Research advances in the pharmacotherapy of drug-resistant Acinetobacter baumannii

Phage P2-71 against multi-drug resistant Proteus mirabilis: isolation, characterization, and non-antibiotic antimicrobial potential

Isolation, characterization, and potential application of Acinetobacter baumannii phages against extensively drug-resistant strains